RCVi（Bravovax）

N/A

Report date: 2024/12/20 14:34:31

Base Information

Drug NameRCVi（Bravovax）
Drug Alias NameRecombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation（Bravovax）吸入用重组新型冠状病毒疫苗(黑猩猩腺病毒载体)（博沃生物）RCViRecombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
ClassificationVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionSARS-CoV-2 Spike glycoprotein receptor binding domain antagonists
TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWuhan Bravovax Co LtdShanghai Bravobio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bravobio Co LtdWuhan Bravovax Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A